肝动脉输液化疗加regorafenib与单独regorafenib相比作为高级肝细胞癌的二线治疗:一个随机对照试验协议
He Zhao1,2, Xiaowu Zhang1, Pengfei Tian1
1Department of Interventional Therapy, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
BMJ open
|December 7, 2024
概括
这项研究评估了肝动脉输液化疗 (HAIC) 加regorafenib治疗晚期肝细胞癌 (aHCC). 它将这种组合与单独使用regorafenib进行二线治疗,评估整体存活率和安全性.
科学领域:
- 肝胆道恶性瘤 肝胆道恶性瘤
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 肝动脉输液化疗 (HAIC) 在晚期肝细胞癌 (aHCC) 中的作用尚不清楚.
- 以前的研究表明,HAIC与索拉芬尼结合在一线aHCC治疗中优于单独的索拉芬尼.
研究的目的:
- 评估HAIC与regorafenib结合的有效性和安全性,作为高级肝细胞癌 (aHCC) 的二线治疗.
主要方法:
- 一个多中心,开放标签,随机控制的III期试验,涉及294名aHCC患者.
- 患者被随机分配 (2:1) 接受HAIC加regorafenib或单独使用regorafenib.
- 主要终点是整体存活率;次要终点包括无进展生存率和整体反应率.
主要成果:
- 关于主要结果的数据尚未提供,因为这是试验注册摘要.
结论:
- 关于结论的数据尚未提供,因为这是试验注册摘要.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...